IVIG in Dermatology: Indications and Protocols

Overview / Definition Intravenous immunoglobulin (IVIG) is a blood product consisting of pooled immunoglobulin G (IgG) antibodies extracted from the plasma of thousands of donors. It is utilized in various clinical settings, particularly for immunomodulation and treatment of autoimmune diseases, including certain dermatological conditions. Epidemiology IVIG therapy has gained traction in dermatology over the past few decades. The incidence of conditions treated with IVIG varies, but certain diseases, such as pemphigus vulgaris, are more prevalent in specific demographics, notably middle-aged adults. Additionally, autoimmune blistering diseases are more common in females than males. Pathophysiology / Mechanism The exact mechanism of action of IVIG in dermatology remains partially understood but is believed to involve several pathways: Neutralization of pathogenic autoantibodies. Modification of the immune response through Fc receptor blockade. Regulation of cytokine production and enhancement of regulatory T cells. Stimulation of complement pathways leading to altered immune complex clearance. Clinical Presentation Conditions treated with IVIG in dermatology often present with distinctive clinical features. Pemphigus vulgaris, for example, manifests with painful mucosal and skin blisters. Dermatomyositis can present with characteristic heliotrope rashes and muscle weakness, while toxic epidermal necrolysis (TEN) may lead to widespread skin detachment and systemic complications. Diagnosis / Workup Diagnosis of conditions requiring IVIG typically involves: Clinical evaluation and history-taking. Biopsy and histopathological examination to confirm autoimmune blistering diseases. Serologic tests for autoantibodies, such as anti-desmoglein in pemphigus. Evaluation of associated comorbidities, especially in conditions like dermatomyositis. Treatment / Management IVIG is administered in various dosing protocols, generally tailored to the specific condition and severity: Pem